{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T12:06:07Z","timestamp":1790251567006,"version":"4.1.0"},"reference-count":17,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T00:00:00Z","timestamp":1790208000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"abstract":"<jats:p>Large-scale clinical studies investigating the safety and efficacy of novel therapeutics in ovarian cancer rarely include Black women or women of African ancestry. The sampled population in the PRIMA study was only 1.6% Black. Our objective is to evaluate the safety and tolerability of maintenance niraparib treatment in women of African ancestry. We hypothesize that the Poly (ADP-ribose) polymerase inhibitor (PARP) niraparib administered at standard doses in a population of African ancestry may demonstrate different safety and efficacy profiles to those in the PRIMA trial who were of primarily European ancestry. We will conduct a prospective, single-arm, multicenter, international study of 70 women of African ancestry designed to evaluate the safety and efficacy of niraparib maintenance therapy following completion of primary treatment for epithelial ovarian cancer. Study sites will include the United States, Bahamas, and Nigeria. Eligible patients must have histologically confirmed high-grade serous or endometrioid ovarian carcinoma, completed primary treatment for newly diagnosed stage III or IV ovarian, fallopian tube, or primary peritoneal carcinoma (surgery and chemotherapy) with partial or complete response, and self-identify as Black or African or Afro-Caribbean. The primary endpoint is the proportion of women with any grade 3 or higher adverse event. Secondary endpoints and translational endpoints will include progression free survival, pharmacokinetics, quality of life assessments, and biomarkers of PARP inhibitor resistance and metabolism.<\/jats:p>\n                  <jats:sec>\n                    <jats:title>Clinical Trial Registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/clinicaltrials.gov\/study\/NCT06412120<\/jats:ext-link>\n                      , identifier NCT06412120.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fonc.2026.1976278","type":"journal-article","created":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:17:40Z","timestamp":1790248660000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Prospective multicenter study evaluating safety, tolerability and metabolism of niraparib as maintenance for ovarian cancer in women of African ancestry"],"prefix":"10.3389","volume":"16","author":[{"given":"Matthew","family":"Schlumbrecht","sequence":"first","affiliation":[{"name":"Sylvester Comprehensive Cancer Center","place":["Miami, FL, United States"]},{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Miami Miller School of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bala","family":"Audu","sequence":"additional","affiliation":[{"name":"Federal University of Health Sciences Azare (FUHSA)","place":["Azare, Bauchi State, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed","family":"Hamidu","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital (ABUTH)","place":["Zaria, Kaduna State, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aisha","family":"Mustapha","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital (ABUTH)","place":["Zaria, Kaduna State, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adekunle","family":"Oguntayo","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital (ABUTH)","place":["Zaria, Kaduna State, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anisah","family":"Yahya","sequence":"additional","affiliation":[{"name":"Ahmadu Bello University Teaching Hospital (ABUTH)","place":["Zaria, Kaduna State, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Abubakar","family":"Bello","sequence":"additional","affiliation":[{"name":"Federal University of Health Sciences Azare (FUHSA)","place":["Azare, Bauchi State, Nigeria"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raleigh","family":"Butler","sequence":"additional","affiliation":[{"name":"University of the West Indies-Nassau","place":["Nassau, Bahamas"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darron","family":"Halliday","sequence":"additional","affiliation":[{"name":"University of the West Indies-Nassau","place":["Nassau, Bahamas"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saida","family":"Bowe","sequence":"additional","affiliation":[{"name":"University of the West Indies-Nassau","place":["Nassau, Bahamas"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Scott","family":"Jordan","sequence":"additional","affiliation":[{"name":"Broward Health","place":["Fort Lauderdale, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karina","family":"Hew","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, University of Florida-Jacksonville","place":["Jacksonville, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre","family":"Pinto","sequence":"additional","affiliation":[{"name":"Department of Pathology, University of Miami Miller School of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. Patricia","family":"Castillo","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Miami Miller School of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isildinha M.","family":"Reis","sequence":"additional","affiliation":[{"name":"Division of Biostatistics and Bioinformatics, Department of Public Health Sciences, University of Miami Miller School of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophia","family":"George","sequence":"additional","affiliation":[{"name":"Sylvester Comprehensive Cancer Center","place":["Miami, FL, United States"]},{"name":"Department of Obstetrics, Gynecology, and Reproductive Sciences, University of Miami Miller School of Medicine","place":["Miami, FL, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,24]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"10","DOI":"10.3322\/caac.21871","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J Clin"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1038\/nature10166","article-title":"Integrated genomic analyses of ovarian carcinoma","volume":"474","year":"2011","journal-title":"Nature"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.ccr-16-1119","article-title":"Racial\/ethnic disparities in ovarian cancer treatment and survival","volume":"22","author":"Bandera","year":"2016","journal-title":"Clin Cancer Res"},{"key":"B4","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/j.ygyno.2019.03.007","article-title":"Identifying disparities in germline and somatic testing for ovarian cancer","volume":"153","author":"Huang","year":"2019","journal-title":"Gynecol Oncol"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.5005\/jp\/books\/10971_25","article-title":"Gene sequencing for pathgenic variants among adults with breast and ovarian cancer in the Caribbean","volume":"4","author":"George","year":"2021","journal-title":"JAMA Netw Open"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1200\/jco.18.02238","article-title":"Niraparib maintenance therapy in patients with recurrent ovarian cancer after a partial response to the last platinum-based chemotherapy in the ENGOT-OV16\/NOVA trial","volume":"37","author":"del Campo","year":"2019","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2020.38.15_suppl.6051","article-title":"Niraparib in patients with newly diagnosed advanced ovarian cancer","volume":"381","author":"Monk","year":"2019","journal-title":"N Engl J Med"},{"key":"B8","unstructured":"American Community Survey 5-Year Data (2009-2021)\n          \n          \n          2022"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.5771\/9781442227392-107","article-title":"Key facts about black immigrants in the U.S","author":"Anderson","year":"2018","journal-title":"Pew Res Center"},{"key":"B10","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2018.78.3977","article-title":"Inherited breast cancer in nigerian women","volume":"36","author":"Zheng","year":"2018","journal-title":"J Clin Oncol"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1038\/sj.clpt.6100080","article-title":"Enhancing race-based prescribing precision with pharmacogenomics","volume":"81","author":"Nguyen","year":"2007","journal-title":"Clin Pharmacol Ther"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1002\/cpt.2549","article-title":"Warfarin dosing in patients with CYP2C9*5 variant alleles","volume":"111","author":"Lindley","year":"2022","journal-title":"Clin Pharmacol Ther"},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.1097\/fpc.0000000000000467","article-title":"Population genetic polymorphisms of pharmacogenes in Zimbabwe, a potential guide for the safe and efficacious use of medicines in people of African ancestry","volume":"32","author":"Mbavha","year":"2022","journal-title":"Pharmacogenet Genomics"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007679","article-title":"Absolute neutrophil count by Duffy status among health Black and African American adults","volume":"7","author":"Merz","year":"2023","journal-title":"Blood Adv"},{"key":"B15","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pgen.1000360","article-title":"Reduced neutrophil count in people of African descent is due to a regulatory variant in the Duffy antigen receptor for chemokines gene","volume":"5","author":"Reich","year":"2009","journal-title":"PloS Genet"},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2025.3869","article-title":"Duffy null-associated absolute neutrophil counts and cancer clinical trial eligibility","volume":"11","author":"Merz","year":"2025","journal-title":"JAMA Oncol"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1001\/jamaoncol.2023.2283","article-title":"Treatment with niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer","volume":"9","author":"Li","year":"2023","journal-title":"JAMA Oncol"}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1976278\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T11:17:42Z","timestamp":1790248662000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fonc.2026.1976278\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,24]]},"references-count":17,"alternative-id":["10.3389\/fonc.2026.1976278"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2026.1976278","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,24]]},"article-number":"1976278"}}